作为业绩稳增长的基建+大消费的白马股，上海实业控股（00363）凭借高股息，低估值一直受到投资 者的高度关注。 9月17日，智通财经携手星耀资本，于中国新经济与电商的活力之都——杭州，启幕"大消费投资高峰论 坛暨2025智通星耀秋季联合策略会"。在路演环节，上海实业控股就公司发展现状、未来发展以及分红 回报等与现场投资者做了汇报，以及零距离深度沟通。 根据上海实业控股近期发布的上半年财报，实现营收94.76亿港元，归母净利润10.42亿港元。分业务 看，基建环保和消费品构建了强大的业绩基本盘，贡献了核心的业绩，期间分别贡献净利润9.33亿港元 及4.03亿港元。值得注意的是，上半年国内房地产行业仍处于"去库存、调结构"的转型阶段，该公司对 部分项目存货及投资物业计提合计11.5亿港元减值拨备，拉低了整体盈利水平。 不过，该公司仍保持加大股东回报力度的一贯做法，宣布拟派中期股息每股42港仙，派息率43.8%，股 息率达到6.4%。 其次大消费赛道，消费品业务是公司稳健现金流的第二大核心业务，包括南洋烟草及永发印务，消费品 业务受经济大环境影响，业绩弹性较大，近几年消费持续回暖，该业务于2023-2025年半年度 ...

Core Viewpoint - Longshen Rongfa (300534) reported a net profit increase of 27.48% for the first half of 2025, despite a decline in total revenue by 8.21% compared to the previous year [1] Financial Performance - Total revenue for the first half of 2025 was 496 million yuan, down from 541 million yuan in 2024, representing an 8.21% decrease [1] - Net profit attributable to shareholders reached 27.96 million yuan, up from 21.93 million yuan in 2024, marking a 27.48% increase [1] - The gross profit margin decreased to 66.19%, down 13.38% year-on-year, while the net profit margin increased to 8.25%, up 18.99% [1] - Total operating expenses (selling, administrative, and financial) amounted to 248 million yuan, accounting for 50.05% of revenue, a decrease of 20.43% [1] - Earnings per share rose to 0.09 yuan, a 27.52% increase from 0.07 yuan in 2024 [1] Cash Flow and Debt - Operating cash flow per share was -0.21 yuan, a significant decrease of 129.82% year-on-year, attributed to reduced sales collections and increased payments related to operating activities [1][3] - The company’s monetary funds decreased by 39.05% to 215 million yuan, while accounts receivable increased by 27.52% to 235 million yuan [1] Business Model and Product Development - The company relies heavily on research and marketing to drive performance, with a historical return on invested capital (ROIC) of 5.51%, indicating average capital returns [3] - Longshen Rongfa is focused on the development of its main products, including the unique "Yuanhu Zhitong Dwan," which has been recognized for its efficacy in treating various types of pain [5][6] - The company is actively pursuing the second development of major products and enhancing its technological barriers through various research projects [6] Market Strategy and Future Outlook - The company is optimistic about the health sector and is expanding its product offerings in this area, including various health products [7] - It aims to leverage its advantages in the traditional Chinese medicine industry, supported by recent government policies promoting the sector [9] - The company plans to enhance its quality management system and increase R&D investments to develop more high-quality products [9]

Group 1 - The core point of the article is that Tuoxin Pharmaceutical has invested 10 million yuan in Jiangsu Jinsan Biotechnology Co., Ltd., acquiring a 1.75% stake, which will enhance its capabilities in the health sector [1][3] - The investment agreement stipulates that the funds will be used solely for the development and operation of Jinsan Biotechnology's main business [1] - Tuoxin Pharmaceutical is actively expanding into the health sector, developing nutritional supplements, food additives, and health foods, with successful mass production of certain functional foods [1][2] Group 2 - In 2024, Tuoxin Pharmaceutical has focused on "technological innovation, dynamic product structure optimization, and deep integration of the industrial chain" to address core business fluctuations and cultivate new growth points [2] - The company has established multiple technology platforms, including chemical synthesis and synthetic biology, and has improved the conversion of R&D results [2] - Tuoxin Pharmaceutical plans to accelerate the R&D and registration of health products over the next three years, aiming to create a complete commercialization chain [2] Group 3 - Jinsan Biotechnology specializes in the research, production, and application of ergotioneine, with breakthroughs in fermentation and purification technologies [3] - The main products of Jinsan Biotechnology include skincare products, oral capsules, and eye wash solutions [3] - Tuoxin Pharmaceutical's investment in Jinsan Biotechnology is a strategic move to extend its production, sales, and R&D chain, enhancing market competitiveness and profitability [3]

Nationalization Strategy - The nationalization strategy of Gujinggongjiu is a necessary choice for long-term development and an important way to achieve scale expansion and performance growth, with a current national coverage rate exceeding 70%, and a provincial structure ratio of 6:4 [1] - The company aims to develop its nationalization strategy from "horizontal" to "vertical," with core markets outside the province becoming another engine for rapid growth [1] - By building a number of large provincial markets and customers outside the province, Gujinggongjiu is expected to further increase sales scale and market share in these areas [1] "Baijiu+" Strategy - The "Baijiu+" strategy is forward-looking and innovative, helping the company to expand its business boundaries and meet diverse consumer needs, including the integration of Baijiu with traditional Chinese medicine, low-alcohol products, and the food industry [1] - Transitioning products into commodities, upgrading commodities to bestsellers, and evolving star products into perennial favorites presents significant challenges [1] Growth Opportunities - The company will continue to optimize its product structure, using Gu20 as a strategic pivot to capture the sub-high-end consumer group while expanding market share for popular products like Gu8, Gu5, and other traditional offerings [1] - The growth of sub-high-end products significantly enhances the company's overall profitability and meets consumer demand for high-quality Baijiu [2] Expansion in Health Sector - Gujinggongjiu is accelerating its entry into the health sector with the "Baijiu + Health" strategy, launching innovative products like herbal-flavored whiskey, which may help the company secure a position in the health beverage market [2] - New beverage offerings from Anhui Gujing Health Technology Co., such as 100% coconut water and herbal fermented drinks, provide new business growth points for the company [2] Innovative Consumer Experiences - The company is creating new consumer experiences by integrating brand and culture through innovative consumption scenarios, which better meet the needs of younger consumers and enhance brand loyalty [3] Mergers and Acquisitions - Gujinggongjiu's acquisition of Hubei Huanghelou Liquor Co. demonstrates strong execution in resource integration and strategic expansion, providing potential for achieving a revenue target of 30 billion [3]

Core Viewpoint - Ximai Foods, known as "China's Oatmeal First Stock," has outlined its plans for the next 3-5 years, focusing on health food centered around oats and expanding its market share, particularly in the cold oatmeal sector and the broader health industry [1][3] Group 1: Company Performance - Ximai Foods aims to achieve a 15% revenue increase by 2025, despite facing a declining net profit margin over the past five years [1][3] - From 2019 to 2024, Ximai Foods' revenue grew from 973 million to 1.896 billion, while net profit margin decreased from 16.18% to 7.02% [3][4] Group 2: Cost Pressures - The company is experiencing significant cost pressures, particularly due to rising raw material costs, with a 27.13% increase in operating costs in 2024, outpacing the 20.16% revenue growth [4][5] - Ximai Foods relies heavily on Australian oats, which constitute about 90% of its raw material supply, making it vulnerable to price fluctuations and supply issues [4][5] Group 3: Strategic Initiatives - To mitigate costs, Ximai Foods plans to increase the use of domestic oats and is developing a stable supply chain, including a new production base in Zhangbei [4][5] - The company is diversifying its product offerings by entering the health sector, launching various protein powders and beverages, although these new products currently contribute a small percentage to total revenue [6][7] Group 4: Market Challenges - The overall oatmeal market is experiencing slowed growth, with a significant decline noted in 2022, prompting Ximai Foods to seek new growth avenues in the health sector [6][7] - The competitive landscape in the health market is intense, with established players dominating, posing challenges for Ximai Foods as a new entrant [7][8]

Group 1: Company Development Plans - The company aims to maintain its position as the leading player in the oat industry over the next 3-5 years, focusing on health food products primarily based on oats [1][2] - Plans to expand into the cold oat food market and develop new health products [2][3] - The company will enhance its offline channel dominance while adapting to new channel trends [2][5] Group 2: E-commerce Strategy - The company has seen rapid growth in sales on the Douyin platform and is adjusting its product structure to include higher value-added products [2][3] - Strategies to optimize sales methods on e-commerce platforms include adjusting the ratio of live broadcasts and influencer promotions [2][3] Group 3: Product Development and Consumer Trends - New product development will focus on meal replacement and functional needs, responding to the growing demand in these segments [3][4] - The company is shifting its target demographic from primarily older consumers to include younger consumers, with over 35% of buyers aged 30-40 and about 10% aged 18-25 [3][4] Group 4: Channel Adaptation - Despite a decline in offline supermarket traffic, the company continues to experience growth in offline sales by embracing channel changes [4][5] - The company is leveraging community, private domain, and membership warehouse channels to achieve rapid sales growth [5] Group 5: Raw Material Sourcing - The company uses Australian oats due to their high quality and mature supply chain, while gradually increasing the use of domestic oats [5] - A new oat production base in Zhangbei is set to enhance the integration of planting, grain collection, and processing [5]

Investment Rating - The investment rating for the company is "Outperform the Market" [5][30] Core Views - The company's revenue for 2024 is projected to be CNY 238.87 billion, a decrease of 5.03% year-on-year, while the net profit attributable to shareholders is expected to be CNY 2.50 billion, down 12.14% year-on-year. However, the first quarter of 2025 shows a positive trend with a revenue increase of 3.15% year-on-year to CNY 59.08 billion and a net profit increase of 11.24% year-on-year to CNY 0.98 billion [8][12] - The company is actively expanding into the health sector, establishing a dedicated department for this purpose, and has launched high-end products such as glycerol diester oil (DAG) and low GI products [2][12] - The company anticipates a moderate increase in raw material prices in 2025, which is expected to benefit its performance as the market recovers [8][12] Summary by Sections Financial Performance - In 2024, the company achieved a total revenue of CNY 238.87 billion, a decrease of 5.03% year-on-year, with a total profit of CNY 3.66 billion, an increase of 7.05% year-on-year. The net profit attributable to shareholders was CNY 2.50 billion, down 12.14% year-on-year [8][12] - The first quarter of 2025 showed a revenue increase of 3.15% year-on-year to CNY 59.08 billion and a net profit increase of 11.24% year-on-year to CNY 0.98 billion [8][12] Business Segments - The kitchen food business saw a total sales volume of 24.07 million tons in 2024, an increase of 4% year-on-year, although revenue decreased by 6% to CNY 147.6 billion due to falling raw material prices [2][12] - The feed raw materials and oil technology business experienced a sales volume of 29.65 million tons in 2024, a 10% increase year-on-year, with revenue of CNY 91.6 billion, down 10% year-on-year [3][15] Profitability and Forecasts - The company expects net profits for 2025-2027 to be CNY 3.14 billion, CNY 3.65 billion, and CNY 3.91 billion respectively, with corresponding P/E ratios of 55, 47, and 44 [3][25] - The gross margin improved to 5.35% in 2024, while the net margin slightly decreased to 1.03% [19][24]

Core Insights - The company reported a revenue of HKD 1,611.6 million for the year ending December 31, 2024, representing a year-on-year growth of 5.7% [1] - The net profit for the same period was HKD 529.2 million, with a profit attributable to shareholders of HKD 500.3 million, resulting in an earnings per share of HKD 0.60 [1] - The board proposed a final dividend of HKD 0.35 per share [1] Hong Kong Market Performance - The company achieved revenue of HKD 1,069.7 million in the Hong Kong market, marking a year-on-year increase of 16.9% [2] - Despite challenges in the retail sector, the company successfully implemented a major product strategy and enhanced market promotion, leading to a recovery in retail revenue in the second half of the year [2] - The company added 2 new retail outlets in Hong Kong during the year [2] Overseas Market Expansion - The company generated revenue of HKD 402.6 million from overseas markets, with a total of 47 retail outlets [2] - The company is focused on promoting traditional Chinese medicine culture internationally and expanding its market presence [2] - Revenue from the domestic distribution business in mainland China was HKD 139.4 million, indicating a gradual recovery [2] Production and R&D Strengthening - The company enhanced its core business by focusing on production quality management and technological innovation [3] - The production facility in Tai Po, Hong Kong, holds multiple certifications, ensuring high-quality product manufacturing [3] - The company has developed a comprehensive quality control system covering all stages from project initiation to production [3] New Product Development - The company launched several new products, including anti-aging NMN series and various herbal formulations, expanding its product matrix [4] - The company received approval for the registration of Angelica Blood Supplement Granules, further diversifying its product offerings [4] - Collaborations with universities and research institutions are ongoing to promote scientific research and product development [4] Intellectual Property Strategy - The company has accumulated 75 authorized patents and filed 8 international PCT applications as of December 31, 2024 [5] - The focus on developing new health products aligns with market trends and consumer demands [5] - The company aims to strengthen its competitive edge through robust intellectual property development [5] Brand Promotion and Market Influence - The company has intensified brand promotion efforts to enhance its international market presence [6] - Key brand activities included "Tong Ren Tang Day" and "9th Tong Ren Care Stroke Prevention," aimed at showcasing the company's cultural heritage [6] - Participation in various exhibitions has helped the company demonstrate its international development and traditional medicine culture [6] Marketing Strategies - The company has leveraged various media platforms to promote its products and traditional Chinese medicine research [7] - Marketing efforts include seasonal health education campaigns and enhanced e-commerce strategies through partnerships with major online platforms [7] - The company received multiple awards, reinforcing its brand reputation and market position [7] Future Outlook - The company anticipates new growth opportunities in the traditional Chinese medicine sector driven by supportive national policies and rising market demand [9] - Strategic initiatives for 2025 include cost reduction, efficiency enhancement, and optimizing management and investment strategies [9] - The company aims to solidify its leading position in both domestic and international markets while contributing to the sustainable development of the traditional Chinese medicine industry [9]